JP2024546121A - Ｍａｌｔ１阻害剤を使用して疾患を処置する方法 - Google Patents

Ｍａｌｔ１阻害剤を使用して疾患を処置する方法 Download PDF

Info

Publication number
JP2024546121A
JP2024546121A JP2024534494A JP2024534494A JP2024546121A JP 2024546121 A JP2024546121 A JP 2024546121A JP 2024534494 A JP2024534494 A JP 2024534494A JP 2024534494 A JP2024534494 A JP 2024534494A JP 2024546121 A JP2024546121 A JP 2024546121A
Authority
JP
Japan
Prior art keywords
malt1 inhibitor
malt1
subject
administration
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024534494A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024546121A5 (enExample
Inventor
ビスワス，スバブラタ
ラオ，パトリシア・イレイン
フォックス，バーバラ・サクストン
ラバー，ダニア・ムニル
ロング，アンドリュー・ジョン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rarefied Biosciences Inc
Original Assignee
Rarefied Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rarefied Biosciences Inc filed Critical Rarefied Biosciences Inc
Publication of JP2024546121A publication Critical patent/JP2024546121A/ja
Publication of JP2024546121A5 publication Critical patent/JP2024546121A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2046—IL-7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024534494A 2021-12-10 2022-12-09 Ｍａｌｔ１阻害剤を使用して疾患を処置する方法 Pending JP2024546121A (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US202163288085P 2021-12-10 2021-12-10
US202163288081P 2021-12-10 2021-12-10
US202163288083P 2021-12-10 2021-12-10
US63/288,083 2021-12-10
US63/288,081 2021-12-10
US63/288,085 2021-12-10
US202263306655P 2022-02-04 2022-02-04
US202263306657P 2022-02-04 2022-02-04
US202263306660P 2022-02-04 2022-02-04
US63/306,655 2022-02-04
US63/306,660 2022-02-04
US63/306,657 2022-02-04
PCT/US2022/052450 WO2023107721A1 (en) 2021-12-10 2022-12-09 Methods for treating diseases using malt1 inhibitors

Publications (2)

Publication Number Publication Date
JP2024546121A true JP2024546121A (ja) 2024-12-17
JP2024546121A5 JP2024546121A5 (enExample) 2025-10-27

Family

ID=86731143

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024534494A Pending JP2024546121A (ja) 2021-12-10 2022-12-09 Ｍａｌｔ１阻害剤を使用して疾患を処置する方法

Country Status (6)

Country Link
US (1) US20250032493A1 (enExample)
EP (1) EP4444340A4 (enExample)
JP (1) JP2024546121A (enExample)
AU (1) AU2022405443A1 (enExample)
CA (1) CA3240140A1 (enExample)
WO (1) WO2023107721A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026526665A (ja) * 2023-06-30 2026-08-10 ヤンセン ファーマシューティカ エヌ．ベー． Ｍａｌｔ１阻害剤
CN122095078A (zh) * 2023-10-18 2026-05-26 北京沙砾生物医药股份有限公司 一种表达融合蛋白的细胞及其应用
WO2025223516A1 (zh) * 2024-04-24 2025-10-30 首药控股(北京)股份有限公司 一种抑制剂杂环化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6069321B2 (ja) * 2011-08-02 2017-02-01 ヘルムホルツ ツェントラム ミュンヘン ドイチェス フォーシュングスツェントラム フュール ゲズントハイト ウント ウンヴェルト ゲーエムベーハーＨｅｌｍｈｏｌｔｚ Ｚｅｎｔｒｕｍ Ｍｕｅｎｃｈｅｎ Ｄｅｕｔｓｃｈｅｓ Ｆｏｒｓｃｈｕｎｇｓｚｅｎｔｒｕｍ Ｆｕｅｒ Ｇｅｓｕｎｄｈｅｉｔ Ｕｎｄ Ｕｍｗｅｌｔ Ｇｍｂｈ フェノチアジン誘導体によるｍａｌｔ１プロテアーゼの選択的阻害
EA201590916A1 (ru) * 2012-11-09 2016-02-29 Корнэлл Юниверсити Низкомолекулярные ингибиторы malt1
EP3374361A1 (en) * 2015-11-13 2018-09-19 Novartis AG Novel pyrazolo pyrimidine derivatives
IL294214B2 (en) * 2019-12-27 2026-04-01 Schrodinger Inc Cyclic compounds and methods of using same
WO2021207343A1 (en) * 2020-04-08 2021-10-14 Rheos Medicines, Inc. Malt1 inhibitors and uses thereof

Also Published As

Publication number Publication date
AU2022405443A1 (en) 2024-05-30
EP4444340A1 (en) 2024-10-16
US20250032493A1 (en) 2025-01-30
CA3240140A1 (en) 2023-06-15
EP4444340A4 (en) 2025-12-24
WO2023107721A1 (en) 2023-06-15

Similar Documents

Publication Publication Date Title
US20250032493A1 (en) Methods for Treating Diseases Using MALT1 Inhibitors
Ito et al. A novel JAK inhibitor, peficitinib, demonstrates potent efficacy in a rat adjuvant-induced arthritis model
US11596632B2 (en) JAK1 pathway inhibitors for the treatment of gastrointestinal disease
US12083114B2 (en) Inhibitors of SARM1 in combination with neuro-protective agents
Bechtel Pruritus in pregnancy and its management
US20170112813A1 (en) Methods of treating autophagy-associated disorders and related pharmaceutical compositions, diagnostics, screening techniques and kits
US9931335B2 (en) Desethylhydroxychloroquine for the treatment of diseases associated with inflammation
UA119767C2 (uk) Лікування b-клітинних злоякісних новоутворень із застосуванням комбінації інгібіторів jak та pi3k
Mitchell et al. LILRA5 is expressed by synovial tissue macrophages in rheumatoid arthritis, selectively induces pro‐inflammatory cytokines and IL‐10 and is regulated by TNF‐α, IL‐10 and IFN‐γ
Biswas et al. Pharmacological inhibition of MALT1 ameliorates autoimmune pathogenesis and can be uncoupled from effects on regulatory T-cells
EP4313023A1 (en) Combination treatment methods of multiple sclerosis
US11583517B2 (en) Dual antagonist of PGD2/DPr2 and Thromboxane A2/TPr receptors and use for treatment of maladaptive immune response or thrombotic diathesis
US20260041685A1 (en) Methods of treating indolent systemic mastocytosis
La Gualana et al. Early decrease of T-bet+ B cells during subcutaneous belimumab predicts response to therapy in systemic lupus erythematosus patients
US20190015397A1 (en) Substance that inhibits p2y12 receptor, for use in the preventive treatment of systemic sclerosis in patients with raynaud's phenomenon and a dysimmunity
Skundric et al. Increased levels of bioactive IL-16 correlate with disease activity during relapsing experimental autoimmune encephalomyelitis (EAE)
Zheng et al. Efficacy and safety of abrocitinib for the treatment of adolescents and adults with moderate-to-severe atopic dermatitis: update of a living systematic review and meta-analysis
CN118715019A (zh) 用于使用malt1抑制剂治疗疾病的方法
Tsuji Pathogenesis and Treatment of Interstitial Lung Disease Accompanied by Anti-melanoma Differentiation-associated Gene 5-positive Idiopathic Inflammatory Myopathies
US20250312332A1 (en) Treatment of muscle fibrosis
US20150216865A1 (en) Methods of treating a bruton's tyrosine kinase disease or disorder
TW202432117A (zh) 用於治療全身性硬化症之可溶性鳥苷酸環化酶活化劑
EP4643863A1 (en) Pharmaceutical composition and use thereof
William et al. SB1578, a Novel Inhibitor of JAK2, FLT3
Bambauer¹ et al. Immunosuppression, and Human Monoclonal Antibodies in Dermatologic Diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251017

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251017